PRE-FRONTAL CORTEX PROCESSING DISORDER GAIT AND LIMB IMPAIRMENTS TREATMENT

Patent №

US 9,682,073

Granted

2017-06-20

Filed 2016

Owner

GILROSE PHARMACEUTICALS, LLC

Lab

AI components

1

hardware

Assignment

Recorded

Dataset

AIPD

2023_r1 edition

Application

15075375

A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.

AI hardwareA61K 31/4458A61B 5/4803A61K 31/454A61K 45/06A61B 5/055A61B 5/4064

AI classification

AI hardware0.99
Machine learning0.04
Speech0.01
Vision0.00
Evolutionary computation0.00
Natural language0.00
Planning0.00
Knowledge representation0.00

Ownership

GILROSE PHARMACEUTICALS, LLC

assignment · 380660244

Assignors

ROSEMAN, BRUCE, KAPLAN, GILLA

On an employer assignment, the assignors are typically the inventors.

© 2026 NYSGPT2525 LLC